US Patent 7,780,987: Scope, Claims, and US Patent Landscape for Stable Controlled-Release Monolithic Oral Coatings

US Patent 7,780,987 claims a pharmaceutical oral dosage form and a manufacturing method using a stable controlled release monolithic coating cured at ≥55°C, where the coating composition is defined by three constrained formulation elements: (i) a neutral ester copolymer (dispersion) based on ethyl acrylate plus methyl acrylate (or specified dispersion substitutions tied to methacrylate/methacrylate language), (ii) polyethylene glycol (PEG) selected from a fixed MW set, and (iii) one or more hydrophilic agents plus pharmaceutically acceptable excipients.

What is the claimed technology in US 7,780,987?

1) Product claim scope (Claim 1)

Claim 1 is a tightly drafted structural-and-process claim covering:

An oral dosage form that is coated with a stable controlled release monolithic coating.
The coating is formed by: 1) coating the oral dosage form with a coating composition to form a coated dosage form, and
2) curing at a temperature of at least 55°C to form the monolithic coating.
The coating composition is limited to “consists essentially of,” meaning the core components are required but limited additional materials are allowed that do not materially change basic and novel characteristics.

Composition elements and quantitative limits:

Neutral ester copolymer (amount 1% to 35% by weight of the coating composition), selected from:
- a 30% aqueous dispersion of a neutral ester copolymer based on ethyl acrylate and methyl methacrylate, or
- a 40% aqueous dispersion of a neutral ester copolymer based on ethyl acrylate and methyl methacrylate, or
- combinations thereof.
Polyethylene glycol (PEG) selected from:
- PEG 6000, 8000, 10000, 20000, or combinations
  and present at 0.1% to 3% by weight of the coating composition.
One or more hydrophilic agent(s) and a pharmaceutically acceptable excipient (not quantified in the claim).

2) Product type limitation (Claims 2 and 5)

Claim 2: dosage form is selected from tablet or capsule.
Claims 5: manufacturing method is also limited to tablet/capsule.

3) Drug payload limitation (Claims 3 and 6)

Claim 3: oral dosage form comprises metformin, a pharmaceutically acceptable salt of metformin, or a combination.
Claim 6: method includes the same metformin payload limitation.

4) Method claim scope (Claim 4)

Claim 4 mirrors Claim 1, but covers the manufacturing method:

coating an oral dosage form with the specified composition to make a coated dosage form, then
curing at ≥55°C to make the stable controlled release monolithic coating,
with the coating composition defined identically to Claim 1.

How narrow or broad are the claims in practice?

A. “Monolithic controlled release coating” scope

The claims are limited to a single-layer monolithic coating rather than multi-part layering architectures. The stability aspect is tied to curing and composition rather than to a separate measurable stability metric in the claim text.

Effect: Competitive designs that use multilayer ER systems, different polymer architectures, or different curing regimes fall outside unless they still meet all claim conditions.

B. “Consists essentially of” creates a functional boundary

“Consists essentially of” is broader than “consists of” but narrower than “comprising.”

Effect: Competitors can include ancillary materials (buffers, plasticizers, pigments, processing aids) if those materials do not materially affect the coating’s basic and novel characteristics. The claim text does not specify whether PEG and hydrophilic agents are the only hydrophilic components allowed, but it does require inclusion of at least one hydrophilic agent.

C. Neutral ester copolymer requirement is a key inclusion constraint

The neutral ester copolymer must be present at 1% to 35% by weight and must come from the specified dispersion types:

30% aqueous dispersion of neutral ester copolymer based on ethyl acrylate and methyl methacrylate
40% aqueous dispersion of neutral ester copolymer based on ethyl acrylate and methyl methacrylate
or combinations

Effect: Substituting a different neutral ester copolymer grade outside these dispersion types risks non-infringement.

D. PEG selection is constrained to a specific MW family

The PEG is limited to PEG 6000, 8000, 10000, 20000 and combinations.

Effect: Use of PEG of different molecular weight (even close) is outside the literal definition.

E. Cure temperature is a process gate

The process must include curing at a temperature of at least 55°C.

Effect: Lower temperature curing processes are outside literal claim scope. Higher temperature curing still meets the “at least” threshold.

F. Metformin is an additional limitation

Claims 3 and 6 narrow to metformin payloads. If a competitor uses the claimed coating with a different API, they could avoid the metformin-specific claims, but still potentially face exposure under Claims 1 and 2 (which do not, in the text you provided, expressly limit to metformin).

What does the claim set cover and what does it exclude? (Scope map)

Covers (literal match pathways)

Product:
- tablet or capsule
- with a stable controlled release monolithic coating
- made by coating composition deposition and curing at ≥55°C
- where the composition contains:
- neutral ester copolymer dispersions (30% or 40% aqueous) in 1% to 35%
- PEG (6000 to 20000) in 0.1% to 3%
- one or more hydrophilic agent(s) and excipients
Method:
- coating + curing at ≥55°C using the same composition constraints
Metformin embodiments:
- same product/method limitations with metformin (or salt/combination)

Likely excludes (based on claim language)

Multi-layer coatings that do not qualify as “monolithic” (unless a court interprets monolithic broadly enough to include certain multi-step structures).
Formulations using PEG outside the MW list.
Neutral ester copolymers not from the specified dispersion types, or outside the 1% to 35% window.
Curing below 55°C.
Payload designs not matching metformin where the asserted claim is 3 or 6.

Key claim construction points for litigation or design-around

1) Neutral ester copolymer selection ambiguity

The claim text you supplied states “neutral ester copolymer … based on ethyl acrylate and methyl acrylate,” but then limits selection to dispersions described as based on ethyl acrylate and methyl methacrylate. The allowable selected group in the claim is anchored to the dispersion descriptions, which include “methyl methacrylate.”

Operational implication: A design that uses a copolymer clearly meeting the dispersion descriptions is closer to literal coverage than one that only meets “methyl acrylate” at the name level but does not match the listed dispersion definitions.

2) Cure step is integral

The claims are not simply “after curing at ≥55°C”; they define the coating formation process. If an accused product is made using different curing parameters, non-infringement arguments typically focus on whether the final product still necessarily results from the claimed process.

3) Hydrophilic agent requirement

The claim requires “one or more of a hydrophilic agent.” The identity is not limited. That creates both:

Broad inclusion for many hydrophilic excipients.
Design-around uncertainty: removing the hydrophilic agent may avoid the claim, but many controlled release coatings use hydrophilicity contributors that might be argued as hydrophilic agents.

4) “Stable controlled release monolithic coating” is not quantified

No dissolution profile or stability metric appears in the provided claim text. That increases interpretive dependence on prosecution history, specification, and expert evidence if litigated.

US patent landscape: how 7,780,987 likely fits (based on claim scope only)

Because you supplied only the claims (not the title, assignee, filing dates, specification, cited references, prosecution history, or related family members), the landscape below is constrained to scope-driven landscape mapping (not inventor network or reference list mining). This is the portion that can be derived strictly from the claim architecture.

A. Competitive hot spots likely adjacent to this patent family

The claim sits at the intersection of three broad technology clusters that generate dense patent activity:

1) Monolithic controlled-release coatings 2) Neutral ester copolymers and aqueous dispersions for ER films 3) PEG/plasticization and hydrophilic modulation in ER films

If an alternative design uses:

a different film-former class (e.g., acrylics other than the specified neutral ester copolymers),
a different plasticizer system not limited to the listed PEG MWs,
or a different curing regime, it can reduce risk against the literal claim.

B. Design-around strategies consistent with claim boundaries

These are direct, claim-language driven avoidance levers:

Lower cure temperature: avoid curing at ≥55°C (if feasible while meeting product specs).
PEG swap outside permitted MW: use a PEG MW not listed (or use a non-PEG plasticizer system).
Neutral ester dispersion substitution: use a polymer dispersion not within the specified 30%/40% aqueous dispersion choices (and/or outside 1% to 35%).
Remove hydrophilic agent(s) or use a system argued not to include hydrophilic agent(s) as contemplated by the claim.
Non-monolithic architecture: if the coating structure is genuinely not monolithic.

C. Risk concentration where multiple constraints overlap

The highest infringement risk exists when a competitor hits all of the following simultaneously:

neutral ester copolymer ER dispersion in the specified range and dispersion concentration,
PEG within the listed MW set and within 0.1% to 3%,
hydrophilic agent included,
curing ≥55°C,
and dosage form is a tablet or capsule,
and asserted claims include metformin if the competitor uses metformin.

Practical implications for R&D portfolio decisions

1) If your product is metformin ER tablets/capsules

Exposure is strongest if your coating uses the same polymer family and PEG MW set under curing ≥55°C and includes hydrophilic agents.

2) If your product is non-metformin

Claims 1 and 2 remain potential exposure targets because the independent claim set you provided does not explicitly limit payload to metformin (the metformin limitation appears only in dependent claims 3 and 6).

3) Formulation flexibility exists outside the claimed axes

The claim is strict about several parameters, but not about the specific identity of the hydrophilic agent(s) or excipient(s), which increases formulation degrees of freedom while still managing whether the system is captured by “consists essentially of.”

Claim-by-claim scope checklist (quick diligence tool)

Claim	What must be true for coverage	Hard gates in the provided text
1	Oral dosage form with stable controlled release monolithic coating made via coating + curing; composition defined	Cure ≥55°C; neutral ester copolymer dispersion (30% or 40% aqueous) at 1% to 35%; PEG in 0.1% to 3% selected from 6000/8000/10000/20000; hydrophilic agent(s) present
2	Claim 1 + dosage form type	Tablet or capsule
3	Claim 1 + metformin payload	Metformin or pharmaceutically acceptable salt or combination
4	Method of manufacturing coated dosage form with same coating composition and cure	Cure ≥55°C; same polymer dispersion and PEG range and hydrophilic agent(s) requirement
5	Claim 4 + dosage form type	Tablet or capsule
6	Claim 4 + metformin payload	Metformin or pharmaceutically acceptable salt or combination

Key Takeaways

US 7,780,987 claims stable controlled release monolithic oral coatings formed by a coating step plus curing at ≥55°C, using a neutral ester copolymer in specified 30%/40% aqueous dispersion options at 1% to 35%, plus PEG (6000 to 20000) at 0.1% to 3%, and one or more hydrophilic agents.
The independent coverage (Claims 1 and 4) is driven primarily by polymer dispersion identity, PEG molecular weight set and loading, presence of hydrophilic agent(s), and curing temperature.
Dependent claims (Claims 3 and 6) add a metformin payload constraint.
Design-around most directly targets cure temperature, PEG MW, polymer dispersion type, and/or coating architecture (monolithic vs alternative structures).

FAQs

1) Does the patent require metformin in Claim 1 or Claim 4?
No. Metformin appears in dependent claims 3 and 6; independent claims 1 and 4 cover the coating system without specifying metformin.

2) What curing temperature threshold is required?
The coating must be cured at at least 55°C.

3) Which PEG molecular weights are explicitly permitted?
PEG 6000, 8000, 10000, and 20000, alone or in combination.

4) What are the polymer composition limits in the coating?
The neutral ester copolymer is present at about 1% to about 35% by weight of the coating composition, using the specified 30% aqueous or 40% aqueous dispersion options listed in the claim group.

5) How strong is the “consists essentially of” limitation for adding other excipients?
It allows additional pharmaceutically acceptable excipients, but they must not materially affect the basic and novel characteristics defined by the claimed composition and coating behavior (as framed in the claim language).

References

US Patent 7,780,987 (claims provided in prompt).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	536173	⤷ Start Trial
Australia	2003211145	⤷ Start Trial
Australia	2003211146	⤷ Start Trial
Canada	2476201	⤷ Start Trial
Canada	2476496	⤷ Start Trial
Cyprus	1112517	⤷ Start Trial
Denmark	1476138	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,780,987

Summary for Patent: 7,780,987